Login Form
| Corporate Media in U.S. Ignores Report N1H1 Vaccine Link to Guillain-Barré Syndrome & The Great Flu Game, Brought to you by Big Pharma | | Print | |
|
H1N1 Vaccine Link to Guillain-Barré Syndrome Kept from Public The letter from the Health Protection Agency, the official body that oversees public health, has been leaked to The Mail on Sunday, leading to demands to know why the information has not been given to the public before the vaccination of millions of people, including children, begins. It tells the neurologists that they must be alert for an increase in a brain disorder called Guillain-Barre Syndrome (GBS), which could be triggered by the vaccine. Read entire article The syndrome, which affects about 1,500 people a year in the UK, attacks the nervous system and can result in temporary paralysis. Its exact cause is unclear but many people affected by it have had a viral or bacterial infection a few weeks earlier. A Health Protection Agency (HPA) spokesman said enhanced surveillance was “routine” when introducing a new vaccine. Read entire article It’s a slick propaganda tool aimed at the kids — “The Great Flu,” an online game sponsored by GlaxoSmithKline, the folks who have started testing their pandemic H1N1 swine flu vaccine on hapless and dim-witted human guinea pigs. It will be lucrative windfall, so propaganda is essential. “British pharmaceutical giant GlaxoSmithKline is set to reap billions as fear of the swine flu pandemic grows. The world’s second-largest drug company has secured orders from 16 countries for 195 million doses of the vaccine it is developing against the H1N1 virus, which has killed more than 740 people worldwide,” reports BusinessWeek.
“The U. S. government has paid pharmaceutical companies $7.9 billion since 2004 to develop the capacity to mass vaccine the entire U.S. population by 2011,” writes Herb Werborg. “Under the perceived threat of H1N1, these plans have been accelerated to include the use of a non FDA approved chemical adjuvant suspected of causing Gulf War Syndrome, circumventing the FDA approval process for this potentially life threatening chemical.” In Britain, the Health Protection Agency has warned that the profitable vaccine may increase Guillain-Barré syndrome. The UK’s medicines watchdog, the Medicines and Healthcare Products Regulatory Agency, is already monitoring reported side effects from Tamiflu and Relenza and it is set to extend that surveillance to the vaccine, according to the Telegraph. Ranji Serious Games — and the toxic and deadly H1N1 vaccine certainly is serious — and GlaxoSmithKline may want to send this “game” (propaganda device) back to the developers to work the rest of the story into the equation. A Google News search this morning returns no mention of the Guillain-Barré Syndrome link to the experimental H1N1 vaccine in the U.S. media.
The story has made the rounds in the British press. “The Health Protection Agency (HPA) has asked doctors to check for increases in a brain disorder called Guillain-Barré syndrome (GBS) once the national vaccination programme begins,” the Telegraph reports. “According to the Mail on Sunday, two letters were posted together to neurologists advising them of the concerns. The first, dated July 29, was written by Professor Elizabeth Miller, head of the HPA’s Immunization Department.” The Times Online, Sky News, and the Daily Mail also ran stories on the warning. Alternative news sites in the United States reported on the link but the New York Times, the Washington Post, and other corporate media sources are silent as of this morning. 28,000 people in the U.S. will participate in a government trial of the experimental H1N1 vaccine. “Volunteers will be checked closely for any side effects. They’ll also be monitored for Guillain-Barre syndrome, which was reported in people who received a swine flu vaccine 33 years ago. It’s a rare syndrome usually triggered by a viral infection, and no one knows for sure if the vaccine is also a trigger,” KPBS reported on August 10. Adult volunteers for the clinical trials will be recruited at 8 separate sites including Emory University in Atlanta, the University of Maryland School of Medicine in Baltimore, Vanderbilt University in Nashville, Baylor College of Medicine in Houston, Children’s Hospital Medical Center in Cincinnati, Group Health Cooperative in Seattle, the University Iowa in Iowa City, and St. Louis University, Deborah Shlian reported for the Examiner on July 28. The initial tests will be of vaccines made by Sanofi-Pasteur, a European company, and CLS Biotherapies, an Australian company that has supplied seasonal flu shots in the U.S. for years. Novartis is also conducting separate trials for FDA licensing. |
